Cabaletta Bio, Inc. (CABA)Healthcare | Biotechnology | Philadelphia, United States | NasdaqGS
3.12 USD
-0.26
(-7.692%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 3.18 +0.06 (1.923%) ⇧ (Aug. 28, 2026, 7:51 p.m. EDT) |
Hot Take ↕ | Aug. 22, 2026, 1:59 a.m. EDT
The investment case here is fractured by a stark divergence between the company's operational narrative and its financial reality. While recent clinical trial results have sparked a 'strong buy' analyst consensus and pushed the stock up significantly, the underlying business remains in a deep value trap. The company has suffered a catastrophic multi-year decline, dropping nearly 86% over the last five years, with the last two years seeing double-digit percentage losses. Fundamentally, the picture is dire: negative earnings, negative free cash flow, and a return on equity of nearly -93%. The balance sheet, while currently liquid, supports a burn rate that makes survival uncertain without further dilution. The short-term outlook is ambiguous. The stock is hovering near its 50-day moving average, showing some resilience after a sharp drop, but the statistical forecasting models offer no directional edge, reflecting the high volatility and lack of clear trend. Options activity confirms this tension: traders are hedging with puts while simultaneously placing speculative bets on a massive upside move, creating a volatile environment unsuitable for steady capital appreciation. There is no dividend to provide any income cushion. For a long-term investor, the combination of deteriorating fundamentals, a history of massive share price erosion, and the inherent risks of a biotech company with no commercial revenue yet makes this a dangerous hold. The 'strong buy' ratings likely reflect a binary bet on a specific drug approval rather than a sound investment in the company's current financial health. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.229960 |
| AutoETS | 0.243987 |
| AutoARIMA | 0.243987 |
| AutoTheta | 0.334639 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 36% |
| H-stat | 2.77 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.075 |
| Excess Kurtosis | 0.23 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 12.21 |
| Market Cap | 528,981,760 |
| Forward P/E | -2.11 |
| Beta | 3.25 |
| Website | https://www.cabalettabio.com |
As of Aug. 22, 2026, 1:59 a.m. EDT: Speculators are positioning defensively with heavy put volume at strikes below the current price ($2.50, $3.00) across multiple expirations, suggesting a fear of further downside. However, there is notable 'new flow' buying of out-of-the-money calls at $5.00 and $5.50 strikes for later dates, indicating a speculative bet on a potential catalyst-driven rally despite the prevailing bearish sentiment.
| Attribute | Value |
|---|---|
| 52 Week Change | 1.3310344 |
| Address1 | 2,929 Arch Street |
| Address2 | Suite 600 |
| All Time High | 26.35 |
| All Time Low | 0.59 |
| Ask | 3.14 |
| Ask Size | 1 |
| Average Analyst Rating | 1.5 - Strong Buy |
| Average Daily Volume10 Day | 5,119,460 |
| Average Daily Volume3 Month | 4,672,333 |
| Average Volume | 4,672,333 |
| Average Volume10Days | 5,119,460 |
| Beta | 3.253 |
| Bid | 3.2 |
| Bid Size | 1 |
| Book Value | 1.256 |
| City | Philadelphia |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 3.12 |
| Current Ratio | 5.789 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 3.37 |
| Day Low | 3.11 |
| Debt To Equity | 12.21 |
| Display Name | Cabaletta Bio |
| Earnings Timestamp | 1,786,624,200 |
| Earnings Timestamp End | 1,794,832,200 |
| Earnings Timestamp Start | 1,794,832,200 |
| Ebitda | -184,115,008 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -1.79 |
| Enterprise Value | 329,593,792 |
| Eps Current Year | -1.35584 |
| Eps Forward | -1.4777 |
| Eps Trailing Twelve Months | -1.38 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 2.9025 |
| Fifty Day Average Change | 0.21749997 |
| Fifty Day Average Change Percent | 0.07493539 |
| Fifty Two Week Change Percent | 133.10344 |
| Fifty Two Week High | 4.23 |
| Fifty Two Week High Change | -1.1100001 |
| Fifty Two Week High Change Percent | -0.2624114 |
| Fifty Two Week Low | 1.42 |
| Fifty Two Week Low Change | 1.6999999 |
| Fifty Two Week Low Change Percent | 1.1971831 |
| Fifty Two Week Range | 1.42 - 4.23 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,572,010,200,000 |
| Float Shares | 141,483,978 |
| Forward Eps | -1.4777 |
| Forward P E | -2.1113892 |
| Free Cashflow | -98,343,000 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 154 |
| Fullday Change | -0.26 |
| Fullday Change Percent | -7.69231 |
| Fullday Price | 3.18 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.0096700005 |
| Held Percent Institutions | 0.94009 |
| Implied Shares Outstanding | 169,545,445 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with autoimmune diseases. The company's lead product candidate is resecabtagene autoleucel, a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T, which is in Phase 1/2 clinical trials for the treatment of dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, juvenile myositis, lupus nephritis, systemic lupus erythematosus, relapsing and progressive multiple sclerosis, mucocutaneous and mucosal pemphigus vulgaris (PV), systemic sclerosis, and generalized myasthenia gravis. It also develops DSG3-CAART, a CAAR T cell therapy that is in Phase 1 clinical trial for the treatment of mucosal PV; and MuSK-CAART, an investigational cell therapy in Phase 1 trial for treating patients with anti-muscle-specific kinase (MuSK) antibody positive myasthenia gravis. It has collaborations with the University of Pennsylvania and the Children's Hospital of Philadelphia; Nanjing IASO Biotherapeutics Co., Ltd; Oxford Biomedica; Autolus Holdings (UK) Limited; and WuXi Advanced Therapies, Inc. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania. |
| Long Name | Cabaletta Bio, Inc. |
| Market | us_market |
| Market Cap | 528,981,760 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_590735322 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -181,318,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 575,606,785 |
| Number Of Analyst Opinions | 8 |
| Open | 3.34 |
| Operating Cashflow | -153,927,008 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | 267 759 3100 |
| Post Market Change | 0.06000018 |
| Post Market Change Percent | 1.9230828 |
| Post Market Price | 3.18 |
| Post Market Time | 1,787,961,086 |
| Previous Close | 3.38 |
| Price Eps Current Year | -2.3011565 |
| Price Hint | 4 |
| Price To Book | 2.4840763 |
| Profit Margins | 0.0 |
| Quick Ratio | 5.64 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.5 |
| Region | US |
| Regular Market Change | -0.26 |
| Regular Market Change Percent | -7.69231 |
| Regular Market Day High | 3.37 |
| Regular Market Day Low | 3.11 |
| Regular Market Day Range | 3.11 - 3.37 |
| Regular Market Open | 3.34 |
| Regular Market Previous Close | 3.38 |
| Regular Market Price | 3.12 |
| Regular Market Time | 1,787,947,201 |
| Regular Market Volume | 3,233,290 |
| Return On Assets | -0.48188 |
| Return On Equity | -0.93205 |
| Sand P52 Week Change | 0.20504117 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 169,545,445 |
| Shares Percent Shares Out | 0.2524 |
| Shares Short | 42,795,914 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 41,009,848 |
| Short Name | Cabaletta Bio, Inc. |
| Short Percent Of Float | 0.2782 |
| Short Ratio | 15.02 |
| Source Interval | 15 |
| State | PA |
| Symbol | CABA |
| Target High Price | 30.0 |
| Target Low Price | 3.0 |
| Target Mean Price | 13.25 |
| Target Median Price | 13.5 |
| Total Cash | 225,100,992 |
| Total Cash Per Share | 1.328 |
| Total Debt | 25,713,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.38 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 2.88055 |
| Two Hundred Day Average Change | 0.23944998 |
| Two Hundred Day Average Change Percent | 0.08312648 |
| Type Disp | Equity |
| Volume | 3,233,290 |
| Website | https://www.cabalettabio.com |
| Zip | 19,104 |